The rationale for Bcl-2 plus BTK inhibition is further supported by preclinical studies in CLL52 and MCL;53 the latter where the combination of venetoclax and ibrutinib is being investigated in two separate phase clinical trials (NCT02419560, phase I study; NCT02471391, phase II study). This evidence concerns the gene BCL2 and mantle cell lymphoma.